NCT03070353已完成2 期
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- AKI reversal
研究概览
简要总结
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
详细描述
A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was < 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Decompensated cirrhosis with acute kidney injury
- •Ager over 18 years old
排除标准
- •Having chronic kidney disease, severe heart or lung disease, severe sepsis
- •Receiving nephrotoxic agents
- •Having history of allergic to Dextran
研究组 & 干预措施
Dextran 40
Experimental
Dextran 40 infusion
干预措施: Dextran 40 (Drug)
结局指标
主要结局
AKI reversal
时间窗: 2 weeks
Reducing creatinine to below 1.5 mg/dl
次要结局
- Mortality(1 year)
研究者
Abhasnee Sobhonslidsuk
Associate professor
Ramathibodi Hospital
相似试验
已完成
1 期
A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male ParticipantsChronic Kidney DiseaseHealthy VolunteersNCT05800444Bayer24
已完成
3 期
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney DiseaseNon-diabetic Chronic Kidney DiseaseNCT05047263Bayer1,584
已完成
2 期
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney DiseaseChronic Kidney DiseaseNCT06522997Bayer1,222
已完成
2 期
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsType 2 Diabetes MellitusChronic Kidney DiseaseNCT05013008Bayer951
已完成
2 期
D-cycloserine in the Management of Chronic Low Back PainLow Back PainPainNCT00125528Thomas J. Schnitzer41